Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 370, Issue 6, 2004, Pages 452-463

  Orallo, Francisco ^a   Álvarez, Ezequiel ^a,b   Basaran, Hélène ^c   Lugnier, Claire ^c  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^c CNRS   (France)

Author keywords

45Ca2+ uptake; cAMP and cGMP production; Cyclic nucleotide phosphodiesterases; Hesperetin; Hesperidin; Rat aorta; Superoxide radicals; Vasorelaxation

Indexed keywords

CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; GLIBENCLAMIDE; HESPERETIN; HESPERIDIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NIFEDIPINE; NORADRENALIN; OKADAIC ACID; PHENAZINE METHOSULFATE; POTASSIUM CHLORIDE; SODIUM; SUPEROXIDE; TETRYLAMMONIUM;

ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CELL CULTURE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM; HEART MUSCLE CELL; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; RAT; SMOOTH MUSCLE CONTRACTILITY; THORACIC AORTA; THROMBOCYTE; VASCULAR RING; VASODILATATION;

2',3'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICAL SCAVENGERS; HESPERIDIN; MALE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; SUPEROXIDES; VASODILATION;

EID: 12144251198     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-004-0994-6     Document Type: Article

References (38)

1. Álvarez E, Orallo F (2001) Preliminary study of the potential vasodilator effects on rat aorta of hesperidin and hesperetin, two flavonoids from citrus fruit [abstract 9P076]. Fundam Clin Pharmacol 15:125
2. Álvarez E, Leiro J, Orallo F (2002) Effect of (-)-epigallocatechin 3-gallate on respiratory burst of rat macrophages. Int Immunopharmacol 2:849-855
3. Beretz A, Anton R, Stoclet JC (1978) Flavonoid compounds are potent inhibitors of cyclic AMP phosphodiesterase. Experientia 34:1054-1055
4. Calderone V, Chericoni S, Martinelli C, Testai L, Nardi A, Morelli I, Breschi MC, Martinotti E (2004) Vasorelaxing effects of flavonoids: investigation on the possible involvement of potassium channels. Naunyn-Schmiedebergs Arch Pharmacol (online publication at http://dx.doi.org/10. 1007/s00210-004-0964-z)
5. Eckly-Michel AE, Martin V, Lugnier C (1997) Involvement of cyclic nucleotide-dependent protein kinases in cyclic AMP-mediated vasorelaxation. Br J Pharmacol 122:158-164
6. Edwards G, Weston AH (1995) Pharmacology of the potassium channel openers. Cardiovasc Drugs Ther 9:185-193
7. Emam AM, Elias R, Moussa AM, Faure R, Debrauwer L, Balansard G (1998) Two flavonoid triglycosides from Buddleja madagascariensis. Phytochemistry 48:739-742
8. Feng MG, Feng GH, Zhou QG (1998) Effects of methylhesperidin on coronary, renal and cerebral circulation in dogs. Chung Kuo Yao Li Hsueh Pao 9:548-550
9. Galati EM, Trovato A, Kirjavainen S, Forestieri AM, Rossitto A, Monforte MT (1996) Biological effects of hesperidin, a Citrus flavonoid (Note III): antihypertensive and diuretic activity in rat. Farmaco 51:219-221
10. Garg A, Garg S, Zaneveld LJ, Singla AK (2001) Chemistry and pharmacology of the Citrus bioflavonoid hesperidin. Phytother Res 15:655-669
11. Ibarra M, Perez-Vizcaíno F, Cogolludo A, Duarte J, Zaragoza-Arnáez F, López-López JG, Tamargo J (2002) Cardiovascular effects of isorhamnetin and quercetin in isolated rat and porcine vascular smooth muscle and isolated rat atria. Planta Med 68:307-310
12. Kameni Tcheudji JF, Lebeau L, Virmaux N, Maftei CG, Cote RH, Lugnier C, Schultz P (2001) Molecular organisation of bovine rod cGMP-phosphodiesterase 6. J Mol Biol 310:781-791
13. Karaki H, Ozaki H, Hori M, Mitsui-Saito M, Amano KI, Harada KI, Miyamoto S, Nakazawa H, Won KJ, Sato K (1997) Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev 49:157-230
14. Keravis TM, Wells JN, Hardman JG (1980) Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertibility of major forms. Biochim Biophys Acta 613:116-129
15. Knapp J, Boknik P, Linck B, Luss H, Muller FU, Petertonjes L, Schmitz W, Neumann J (2000) Cantharidin enhances norepinephrine-induced vasoconstriction in an endothelium-dependent fashion. J Pharmacol Exp Ther 294:620-626
16. Komas N, Lugnier C, Stoclet JC (1991) Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol 104:495-503
17. Liu H, Xiong Z, Sperelakis N (1997) Cyclic nucleotides regulate the activity of L-type calcium channels in smooth muscle cells from rat portal vein. J Mol Cell Cardiol 29:1411-1421
18. Lorenz JN, Bielefeld DR, Sperelakis N (1994) Regulation of calcium channel current in A7r5 vascular smooth muscle cells by cyclic nucleotides. Am J Physiol 266:C1656-C1663
19. Lugnier C, Komas N (1993) Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur Heart J 14:141-148
20. Lugnier C, Schini V (1990) Characterization of cyclic nucleotide phosphodiesterases in bovine aortic endothelial cells in culture. Biochem Pharmacol 39:75-84
21. Lugnier C, Schoeffter P, Le Bee A, Strouthou E, Stoclet JC (1986) Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 35:1743-1751
22. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS, Jimmo SL (2003) Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 64:533-546
23. Middleton E Jr, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, cancer. Pharmacol Rev 52:673-751
24. Nichols MR, Morimoto BH (2000) Differential inhibition of multiple cAMP phosphodiesterase isozymes by isoflavones and tyrphostins. Mol Pharmacol 57:738-745
25. 2+ sources. Naunyn-Schmiedebergs Arch Pharmacol 363:612-619
26. Okamura N, Haraguchi H, Hashimoto K, Yagi A (1994) Flavonoids in Rosmarinus officinalis leaves. Phytochemistry 37:1463-1466
27. Orallo F (1996) Regulation of cytosolic calcium levels in vascular smooth muscle. Pharmacol Ther 69:153-171
28. Orallo F (1997) Study of the in vivo and in vitro cardiovascular effects of a hydralazine-like vasodilator agent (HPS-10) in normotensive rats. Br J Pharmacol 121:1627-1636
29. Orallo F, Álvarez E, Camiña M, Leiro JM, Gómez E, Fernández P (2002) The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol 61:294-302
30. + channels? Trends Pharmacol Sci 14:332-337
31. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280-291
32. Sakata K, Hirose Y, Qiao Z, Tanaka T, Mod H (2003) Inhibition of inducible isoforms of cyclooxygenase and nitric oxide synthase by flavonoid hesperidin in mouse macrophage cell line. Cancer Lett 199:139-145
33. Schoeffter P, Lugnier C, Demesy-Waeldele F, Stoclet JC (1987) Role of cyclic AMP- and cyclic-GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta: a study with selective inhibitors. Biochem Pharmacol 36:3965-3972
34. Spencer JP, Chowrimootoo G, Choudhury R, Debnam ES, Srai SK, Rice-Evans C (1999) The small intestine can both absorb and glucuronidate luminal flavonoids. FEBS Lett 458:224-230
35. Stoclet JC, Keravis T, Komas N, Lugnier C (1995) Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases. Expert Opin Investig Drugs 4:1081-1100
36. Van der Zypp A, Rechtman M, Majewski H (2000) The role of cyclic nucleotides and calcium in the relaxation produced by amrinone in rat aorta. Gen Pharmacol 34:245-253
37. Vidrio H, Fernández G, Medina M, Álvarez E, Orallo F (2003) Effects of hydrazine derivatives on vascular smooth muscle contractility, blood pressure and cGMP production in rats: comparison with hydralazine. Vasc Pharmacol 40:13-21
38. 2+-independent contraction of rat aorta. Eur J Pharmacol 293:133-140